Skip to main content

Advertisement

Table 3 Study treatment-related AEs for patients with unresectable hepatocellular carcinoma who underwent either HAIC or TACE

From: Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study

Adverse event Any grade (cases) Grade 3–4 (cases)
HAIC group TACE group P HAIC group TACE group P
Total 35 41 0.110 13 27 0.007
Postembolization syndrome
 Fever 7 30 < 0.001 0 8 0.006
 Pain 30 27 0.219 1 1 1.000
 Vomiting 21 18 0.371 4 1 0.190
Liver dysfunction
 Elevated ALT level 27 38 0.017 1 16 < 0.001
 Hypoalbuminemia 34 27 0.016 0 0 1.000
 Hyperbilirubinemia 13 35 < 0.001 0 3 0.241
Systemic toxicity
 Leukopenia 13 8 0.203 3 1 0.347
 Neutropenia 6 6 1.000 0 1 1.000
 Anemia 27 25 0.477 1 2 1.000
 Thrombocytopenia 13 17 0.643 2 4 0.676
 Anorexia 30 29 0.447 0 0 1.000
 Diarrhea 12 1 0.001 1 0 0.481
 Sensory neuropathy 9 1 0.006 1 0 0.481
Ascites/pleural effusion 2 3 1.000 1 2 1.000
Cholangitis 0 3 0.241 0 2 0.494
Hepatapostema 0 1 1.000 0 1 1.000
Hepatic failure 0 1 1.000 0 1 1.000
Renal failure 2 5 0.434 0 2 0.494
Gastrointestinal bleeding 1 2 1.000 1 2 1.000
  1. AE adverse event; HAIC hepatic artery infusion chemotherapy; TACE transarterial chemoembolization; ALT alanine transaminase
  2. P values were calculated using a two-sided Chi square test